CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a ...

Morningstar brands and products Company Portfolio ...

A downtrend has been apparent in Palatin Technologies, Inc. (PTN) lately. While the stock has lost 9.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed ...

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is ...

CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

(RTTNews) - Palatin Technologies, Inc. (PTN), a biopharmaceutical company, on Thursday announced the completion of its Phase 2 BMT-801 clinical study evaluating the combination of MC4R ...

Fair Value Adjustment Loss: $8.1 million for the quarter ended December 31, 2024. Palatin Technologies Inc (PTN) reported a significant decrease in net cash used in operations, from $10.5 million ...

Operator: Greetings. Welcome to Palatin Technologies, Inc.’s Second Quarter Fiscal Year 2025 Operating Results Conference Call. At this time, all participants are in a listen-only mode.